Study Demonstrates Combining Digital Therapeutics for Insomnia and IAPT Therapy Improves Sleep, Anxiety, and Depression More Than Therapy Alone
Retrieved on:
Wednesday, September 1, 2021
Mental Health, Other Health, Health, Science, Research, People, UnitedHealth Group, Sleep, Lists of diseases, Covert conditioning, Research, Food, Health, Ageing, Hospital, University of Oxford, Oxford University Press, Partnership, Employment, University, National Institute for Health and Care Excellence, Therapy, Innovation, Dementia, NHS Long Term Plan, Accreditation, Insomnia, Mental health, Policy, NIHR, Adult, Sleep medicine, National Institute, Regulation of tobacco by the U.S. Food and Drug Administration, Industry, Bath, Self-management, IAPT, Organic, Depression, FDA, Population, Oxford Health NHS Foundation Trust, Isabella Tree, United States Public Health Service, Anxiety, NICE, CBT, NHS, Education, Psychology, Patient, Pharmaceutical industry, Medicine
Additionally, participants using Sleepio reduced their utilisation of high-intensity IAPT treatment, including personalised therapy delivered by mental health professionals.
Key Points:
- Additionally, participants using Sleepio reduced their utilisation of high-intensity IAPT treatment, including personalised therapy delivered by mental health professionals.
- Recovery rates from standardised IAPT measures used to capture symptoms of anxiety (GAD-7) and depression (PHQ-9) were 65 percent for Sleepio users, versus 58 percent in the control group who received IAPT alone.
- Reflecting on the pandemic, increasingly we'll need more scalable, evidenced digital interventions to augment our services, making care more efficient and effective.
- Poor sleep is rarely specifically addressed in primary care or mental health services, but clinical evidence shows that insomnia significantly impacts comorbid mental health conditions including depression and anxiety.